Filgotinib in Rheumatoid Arthritis: A Profile of Its Use.

Filgotinib (Jyseleca®), an oral Janus kinase (JAK) inhibitor, is approved as monotherapy or in combination with methotrexate to treat moderate to severe active rheumatoid arthritis (RA) in adults who have an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). In phase 3 trials, once-daily filgotinib was generally well tolerated and associated with an improvement in RA signs and symptoms as well as physical function in patients with an inadequate response to ongoing methotrexate, an inadequate response to ongoing conventional synthetic DMARDs plus an inadequate response or intolerance to prior biologic DMARDs, or limited or no prior exposure to methotrexate. In addition, filgotinib was noninferior to adalimumab in terms of low disease activity response rate (DAS28-CRP ≤ 3.2) in patients with an inadequate response to methotrexate. Filgotinib also appeared to inhibit the radiographic progression of joint damage and led to low disease activity or disease remission (DAS28-CRP < 2.6). Filgotinib showed sustained efficacy, and the safety profile of filgotinib longer term was similar to that in the phase 2 and 3 trials.

Adis evaluation of filgotinib in RA

What is the Rationale for Using Filgotinib in RA?

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory joint disease characterized by synovitis that typically develops symmetrically in small joints of the hands and feet [1]. Manifestations include joint swelling, tenderness, warmth and a reduced range of motion. Persistent inflammation can destroy joints and tendons over time, eventually leading to joint deformity. RA can also have extra-articular presentations, with inflammation involving the eyes, skin, heart or lungs [1]. As is the case for most chronic diseases, there is no cure for RA, and the disease will not remit spontaneously [2]. The main therapeutic target for patients with RA is clinical remission, and low disease activity is the best possible alternative [2].

Although the initial cause of RA is unknown, various factors have been implicated in its pathophysiology, including a diverse range of inflammatory cytokines [e.g. tumour necrosis factor, interleukin (IL)-1β, IL-6, interferon (IFN)-γ] [3, 4]. The development of agents targeting cytokines and their receptors, referred to as biologics [or biological disease-modifying antirheumatic drugs (bDMARDs) [2]], was a big advancement in the treatment of autoimmune and inflammatory diseases such as RA [4]. However, targeting a single cytokine does not completely block the progression of RA in all patients, and many bDMARDs lose efficacy over time due to immunogenicity. In addition, the intravenous or subcutaneous routes of administration of bDMARDs may be an obstacle for some patients [4].

Several signal transduction pathways have also been implicated in the progression of RA [3]. For example, the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway facilitates the signal transduction of several cytokines and molecules implicated in RA, including IL-6 and IFN-γ [3]. An increased understanding of cellular pathways downstream of cytokine receptors has led to the development of small orally available molecules, such as those targeting JAKs, that can simultaneously inhibit multiple cytokines involved in RA [4]. JAK inhibitors are classified as targeted synthetic (ts)DMARDs [5].

First-generation JAK inhibitors [e.g. tofacitinib (a JAK1, JAK2 and JAK3 inhibitor) and baricitinib (a JAK1 and JAK2 inhibitor)] have shown effectiveness in improving inflammatory conditions such as RA, but concerns about adverse effects such as cytopenias associated with nonselective pan-JAK blockade have led to the development of second-generation JAK inhibitors with selective inhibitory activity for specific JAKs [4]. Upadacitinib, a JAK1 inhibitor, was the first to be approved [1]. Filgotinib (Jyseleca®) is the most recent second-generation JAK inhibitor to be approved in the EU for the treatment of RA [5, 6].

This article provides an overview of the pharmacological properties of filgotinib and reviews the clinical data relevant to its use in moderate to severe active RA. Discussion of clinical trials evaluating filgotinib for other immune-mediated inflammatory diseases (e.g. ankylosing spondylitis, inflammatory bowel disease, psoriatic arthritis) [7] is beyond the scope of this article.

How Does Filgotinib Work?

Filgotinib is an adenosine triphosphate-competitive and reversible inhibitor of the JAK family [consisting of JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2)] [5, 6]. In biochemical assays, filgotinib inhibited the activity of JAK1 preferentially (IC50 of 10, 28, 810 and 116 nM for JAK1, JAK2, JAK3 and TYK2, respectively) [6, 8]. In human cellular assays, filgotinib showed preferential inhibition of JAK1/3, JAK1/2 and JAK1/TYK2, with functional selectivity over cytokine receptors that signal via pairs of JAK2 or JAK2/TYK2. In vitro, GS-829845 (the primary metabolite of filgotinib) was ≈ tenfold less active than filgotinib, while exhibiting similar preferential inhibition of JAK1 [5]. Pharmacokinetic/pharmacodynamic modelling and simulation using data from healthy volunteers and patients with RA indicates that exposures to GS-829845 are high enough to compensate for its lower potency and the metabolite may therefore contribute to the overall pharmacodynamic effects of filgotinib [9]. In vitro studies in peripheral blood mononuclear cells and whole blood from healthy volunteers and patients with RA and confirmatory ex vivo pharmacodynamic data from healthy volunteers confirmed that filgotinib exhibits preferential inhibition of JAK1. Filgotinib inhibited JAK1-mediated signaling of IFN-α and IL-6 to a similar extent to other JAK inhibitors (tofacitinib, baricitinib, upadacitinib) at doses demonstrating similar efficacy, but showed reduced inhibition of JAK-2 and JAK3-dependent pathways [10].

In patients receiving filgotinib for the treatment of moderate to severe active RA in phase 3 trials [11-13], median platelet counts remained in the normal range but decreased slightly within the first 4 weeks of treatment before becoming stable thereafter through 24 weeks’ therapy [5]. Median haemoglobin values remained stable or slightly increased within the normal range during the 24 weeks, reflecting the decrease in inflammation due to disease control and preferential JAK1 inhibition [14]. Of note, filgotinib treatment is also associated with decreases in serum C-reactive protein (CRP) [as early as 2 weeks after starting treatment and maintained through 24 weeks’ treatment] [5]. In pooled data from phase 2 and 3 studies, decreases in neutrophils, lymphocytes and total leucocytes occurred more frequently in the filgotinib treatment group than in other groups, and a dose-dependent increase in triglycerides, total cholesterol and high-density lipoprotein levels and reduction in low-density lipoprotein levels was seen with filgotinib. LDL/HDL ratios were generally unchanged. Changes in lipid levels occurred in the first 12 weeks of treatment and then stabilized [5, 6].

What is the Pharmacokinetic Profile of Filgotinib?

Filgotinib is absorbed rapidly following oral administration, with a median peak concentration (Cmax) reached 2–3 h post dose (and that of its active circulating metabolite GS-829845 reached 5 h post dose) after multiple dosing [5]. The Cmax and exposure (area under the concentration-time curve) of filgotinib and GS-829845 are similar in healthy adults and in patients with RA, and are dose-proportional over the therapeutic dose range [5].

Filgotinib and GS-829845 reach steady-state concentrations in 2–3 days and 4 days, respectively, with negligible (filgotinib) to ≈ twofold (GS-829845) accumulation after once-daily administration [5]. The administration of filgotinib with a high-fat or low-fat meal compared with a fasted state does not lead to clinically relevant differences in exposure. Human plasma protein binding is low for both filgotinib (55–59%) and GS-829845 (39–44%), and there is no preferential distribution of filgotinib and GS-829845 into blood cells (filgotinib blood-to-plasma ratio 0.85–1.1) [5].

Filgotinib undergoes extensive metabolism, with a low proportion of an orally administered dose recovered unchanged in the urine (≈ 9.4%) and faeces (≈ 4.5%) [5]. Filgotinib is metabolized primarily by carboxylesterase 2 (CES2), and to a lesser extent by CES1, both of which form GS-829845. There are no other major metabolites. Most of the dose (≈ 87%) is eliminated in the urine (54% as GS-829845), and ≈ 15% is eliminated in the faeces (≈ 8.9% as GS-829845). Filgotinib and GS-829845 have mean plasma terminal half-lives of ≈ 7 h and 19 h, respectively [5].

For Whom is Filgotinib Indicated?

Filgotinib is indicated, as monotherapy or in combination with methotrexate, for the treatment of moderate to severe active RA in adults with an inadequate response or intolerance to one or more DMARDs in the EU [5]. Table 1 provides a summary of the prescribing information in the EU.

Table 1

Prescribing summary of filgotinib (Jyseleca®) in the treatment of adults with rheumatoid arthritis in the EU [5]

What is the approved indication of filgotinib?
Treatment of moderate to severe active RA in adults who have responded inadequately to, or who are intolerant to, one or more DMARDs
May be used alone or in combination with methotrexate
How is filgotinib available, and what is the administration regimen?
Availability	Film-coated oral tablets of filgotinib 100 mg or 200 mg
Dosage	200 mg once daily, with or without food; 100 mg once daily in some special populations (see below)
Limitations of use	Not recommended for use in combination with other potent immunosuppressants (e.g. other JAK inhibitors, bDMARDs, azathioprine, ciclosporin, tacrolimus)
What are the contraindications to the use of filgotinib?
Pregnancy (use contraception during treatment and for ≥1 week after cessation of therapy); active TB or active serious infections; hypersensitivity to the active substance or any of the excipients
How should filgotinib be used in special populations?
Pts with chronic kidney disease	Mild disease (CLCR ≥ 60 mL/min): no dose adjustment required
	Moderate or severe disease (CLCR 15 to < 60 mL/min): 100 mg once daily
	Kidney failure (CLCR < 15 mL/min): not recommended
Pts with hepatic impairment	Mild or moderate hepatic impairment (Child-Pugh A or B): no dose adjustment required
	Severe hepatic impairment (Child-Pugh C): not recommended
Elderly pts	In patients aged ≥ 75 years, start with a dosage of 100 mg once daily
Paediatric pts	Safety and efficacy not established in pts aged < 18 years
Breastfeeding women	Do not breastfeed during treatment
What other special warnings/precautions/monitoring requirements pertain to the use of filgotinib?
Infections	Screen pts for TB before initiating treatment; do not administer to pts with active TB; initiate standard antimycobacterial therapy in pts with latent TB before administering filgotinib
	Monitor closely for infections during and after treatment; interrupt treatment if a serious infection develops, or if an infection does not respond to standard antimicrobial therapy, until it is controlled
Viral reactivation	If pt develops herpes zoster, interrupt treatment until the episode resolves
	Screen for viral hepatitis and monitor for reactivation prior to and during treatment
Malignancy	Immunomodulatory products may ↑ the risk of malignancies (as can RA itself)
	Consider the risks and benefits of filgotinib prior to initiating treatment in pts with a known malignancy
Fertility	Discuss the potential risk of reduced fertility or infertility with male pts before treatment initiation
Haematological laboratory abnormalities	ALC < 0.5 × 109 cells/L, ANC < 1 × 109 cells/L, Hb < 8 g/dL: do not initiate or continue treatment
	Reintroduce treatment once the parameters return above these values
Vaccinations	Update immunisations before treatment; do not use live vaccines immediately before or during treatment
Lipids	Check 12 weeks after starting filgotinib, and monitor and manage thereafter
CV risk	Manage risk factors such as hyperlipidaemia and hypertension (RA pts have an ↑ risk for CV disorders)
VTE	Use with caution in pts with risk factors for VTE (e.g. older age, history of VTE, obesity, surgery)
	Discontinue treatment if features of VTE occur, and promptly evaluate/treat
Lactose content (excipient)	Do not use in pts with galactose intolerance, glucose-galactose malabsorption or total lactose deficiency
What are the potential clinically relevant interactions between filgotinib and other drugs?
CYP1A2 substrates with a narrow TI	Caution recommended (in vitro studies were inconclusive, and the potential in vivo effect is unknown)
P-gp or BCRP substrates with a narrow TI (e.g. digoxin)	Caution recommended (in vitro studies were inconclusive, and in vivo inhibition cannot be excluded)
OATP1B1 and OATP1B3 substrates (e.g. valsartan, statins)	Caution recommended (no data; ↑ in their exposure and risk of adverse events cannot be excluded)

ALC absolute lymphocyte count, ANC absolute neutrophil count, bDMARD biological disease-modifying antirheumatic drug, CL creatinine clearance, CV cardiovascular, Hb haemoglobin, JAK Janus kinase, P-gp P-glycoprotein, pts patients, RA rheumatoid arthritis, TB tuberculosis, TI therapeutic index, VTE venous thromboembolism (deep vein thrombosis/pulmonary embolism), ↑ increase(d)

What is the Clinical Efficacy of Filgotinib in RA?

Filgotinib provides effective treatment of moderate to severe active RA in patients with an inadequate response or intolerance to DMARDs, as evidenced by improvements in clinical, patient-reported and radiographic outcomes in randomized controlled trials [11-15]. The efficacy of filgotinib in the treatment of moderate to severe active RA was initially shown in phase 2b trials (DARWIN 1 [14] and DARWIN 2 [15]), in which filgotinib as monotherapy [15] and in combination with methotrexate [14] improved the signs and symptoms of RA in patients who had an inadequate response to methotrexate [14, 15]. The efficacy of filgotinib in patients with moderate to severe active RA was subsequently evaluated in three randomized, double-blind, phase 3 trials (FINCH 1 [11], FINCH 2 [12] and FINCH 3 [13]).

The phase 3 trials enrolled patients aged ≥18 years with moderate to severe active RA (≥ 6 swollen joints from a count of 66 joints and ≥ 6 tender joints from a count of 68 joints) [11-13] and an inadequate response to methotrexate [11], inadequate response to one or two conventional synthetic (cs)DMARD(s) and an inadequate response or intolerance to one or more bDMARDs [12], or limited (< 3 doses ≤ 25 mg) or no prior methotrexate exposure [13]. Patients with an inadequate response to methotrexate had been receiving treatment for ≥ 12 weeks, with the most recent ≥ 4 weeks at a stably prescribed route and dose (in the range of 7.5–25 mg/week) [11, 12]. Patients with an inadequate response to other csDMARDs had been receiving a stable dose of oral hydroxychloroquine (≤ 400 mg/day), chloroquine (≤ 250 mg/day), sulfasalazine (1–3 g/day) or leflunomide (10–20 mg/day) for ≥ 4 weeks [12].

Patients were also required to have one of the following: seropositivity for rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP, also known as ACPA) [11, 13], ≥ 1 joint erosion on hand/wrist or foot radiographs [11, 13] (or ≥ 3 erosions if negative for RF and anti-CCP [11]), or serum CRP level of ≥ 4 mg/L [12, 13] or ≥ 6 mg/L [11].

Key trial design data are presented as part of Table 2. The duration of the trials was 24 weeks [12] or 52 weeks [11, 13]. Concomitant stable doses of non-steroidal anti-inflammatory drugs and/or glucocorticoids (prednisone or equivalent ≤ 10 mg/day) were permitted [11-13]. In FINCH 3, a prior or concomitant stable dose of hydroxychloroquine was also allowed [13]; in FINCH 1, placebo recipients were re-randomized to filgotinib at week 24 [11]. The primary efficacy endpoint was the proportion of patients who achieved ≥ 20% improvement from baseline in the American College of Rheumatology criteria (ACR20) at week 12 (FINCH 1 and 2 [11, 12]) or week 24 (FINCH 3[13]). Primary and key secondary endpoints were tested hierarchically [11-13]. Efficacy analyses were performed in all randomized patients who received ≥ 1 dose of a study drug [11-13].

Table 2

Efficacy of filgotinib in adults with rheumatoid arthritis in the randomized, double-blind, phase 3 FINCH trials

Trial	No of pts	Treatment	ACR20 (% pts)			ACR50 (% pts)			ACR70 (% pts)			HAQ-DI (mean change from baseline)			DAS28-CRP ≤ 3.2 (% pts)			DAS28-CRP < 2.6 (% pts)
			Week
			12a	24b	52	12	24	52	12	24	52	12	24	52	12	24	52	12	24	52
In pts with an inadequate response to MTX (all pts received background MTX during the trial)
FINCH 1c [11]	475	FIL 200	77***†	78***	78	47***†††	58***	62	26***†††	36**†	44	− 0.69***	− 0.82***	− 0.93†	50***†††	61***††	66†	34***††	48***†††	54†
	480	FIL 100	70***	78***	76	36***	53***	59	19***	30***	38	− 0.56***	− 0.75***	− 0.85	39***	53***	59	24***	35***	43
	325	ADA	71***	74	74	35	52	59	14	30	39	− 0.61***	− 0.78	− 0.85	43	50	59	24***	36	46
	475	PL	50	59	NA	20	33	NA	7	15	NA	− 0.42	− 0.62	NA	23	34	NA	9	16	NA
In pts with an inadequate response to csDMARDs and an inadequate response/intolerance to prior bDMARDs (all pts received background csDMARDs during the trial)
FINCH 2 [5, 12]	147	FIL 200	66***	69***	NA	43***	46***	NA	22***	32***	NA	− 0.55***	− 0.75***	NA	41***	48***	NA	22***	31***	NA
	153	FIL 100	58***	55***	NA	32***	35*	NA	14*	20*	NA	− 0.48***	− 0.60**	NA	37***	38**	NA	25***	26**	NA
	148	PL	31	34	NA	15	19	NA	7	8	NA	− 0.23	− 0.42	NA	16	21	NA	8	12	NA
In pts with limited or no prior MTX exposure
FINCH 3 [5, 13]	416	FIL 200 + MTX	77†††	81†††	75†††	53†††	62†††	62†††	33†††	44†††	48†††	− 0.85†††	− 0.94†††	− 1.00†††	56†††	69†††	69†††	40†††	54†††	53†††
	207	FIL 100 + MTX	72††	80†	73††	44†††	57††	59††	27†††	40†††	40†	− 0.77†††	− 0.90††	− 0.97	50†††	63†††	60††	32†††	43†††	43††
	210	FIL 200	71††	78	75†††	46†††	58††	61††	29†††	40†††	45†††	− 0.76†††	− 0.89†	− 0.95†	48†††	60†††	66†††	30†††	42†††	46†††
	416	MTX	59	71	62	28	46	48	13	26	30	− 0.61	− 0.79	− 0.88	29	46	47	17	29	32

ACR20, 50 and 70 ≥ 20%, ≥ 50% and ≥ 70% improvement in American College of Rheumatology criteria, ADA adalimumab 40 mg subcutaneously every 2 weeks, b/csDMARD biological/conventional synthetic disease-modifying antirheumatic drugs, DAS28-CRP Disease Activity Score for 28 joints based on high-sensitivity C-reactive protein level, FIL 100 filgotinib 100 mg orally once daily, FIL 200 filgotinib 200 mg orally once daily, HAQ-DI Health Assessment Questionnaire-Disability Index, MTX methotrexate [in FINCH 3, orally once weekly starting with 10 mg/week, then increasing to 15 mg/week at week 4 (maximum in Japan) and 20 mg/week at week 8], NA not applicable, PL placebo once daily, pts patients*p ≤ 0.05, **p < 0.01, ***p < 0.001 vs PL; †p < 0.05, ††p < 0.01, †††p ≤ 0.001 vs active comparator; values in light grey are exploratory/nominal p-values (not adjusted for multiplicity)

aPrimary endpoint in FINCH 1 and FINCH 2

bPrimary endpoint in FINCH 3 (specifically, the proportion of pts receiving filgotinib 200 mg + MTX achieving ACR20 at week 24)

cNoninferiority of FIL vs ADA established as evaluated by % pts achieving DAS28-CRP ≤ 3.2 at week 12 using a strict hierarchical testing procedure

Inadequate Response to Methotrexate

Filgotinib plus background methotrexate therapy improved the signs and symptoms of RA, improved physical function and inhibited the progression of structural joint damage compared with placebo plus background methotrexate therapy in patients who had moderate to severe active RA despite methotrexate therapy in the FINCH 1 trial [11]. The ACR20 response rate was significantly higher with filgotinib 200 mg and filgotinib 100 mg than with placebo following 12 weeks of treatment (Table 2). Significant improvements with filgotinib compared with placebo were also observed in key secondary endpoints at week 12, including change from baseline score on the Health Assessment Questionnaire-Disability Index (HAQ-DI), and proportion of patients with disease activity scores in 28 joints with CRP (DAS28-CRP) < 2.6 (considered to be disease remission) (Table 2). Of note, filgotinib 200 mg was noninferior to adalimumab for DAS28-CRP ≤ 3.2 (considered low disease activity) at week 12 using a strict hierarchical testing procedure (Table 2). DAS28-CRP ≤ 3.2 and ACR50/70 response rates were also higher with filgotinib at week 12 than with placebo (nominal p < 0.001) (Table 2).

Radiographic progression of joint damage, as assessed by change in van der Heijde modified total Sharp score (mTSS) from baseline to week 24, was significantly (p ≤ 0.001) reduced with filgotinib 200 mg and filgotinib 100 mg versus placebo (0.13 and 0.17 vs 0.37) [11]. Filgotinib showed sustained efficacy through week 52 (Table 2).

Inadequate Response to csDMARDs and Prior bDMARDs

Filgotinib plus background csDMARD therapy improved the signs and symptoms of RA and improved physical function compared with placebo plus background csDMARD therapy in patients who had moderate to severe active RA despite ongoing csDMARD therapy and an inadequate response or intolerance to ≥ 1 prior bDMARD in the FINCH 2 trial [12]. Of note, most patients (81.9%) were receiving methotrexate concomitantly. The ACR20 response rate was significantly higher with filgotinib 200 mg and filgotinib 100 mg than with placebo following 12 weeks of treatment (Table 2). This was independent of the number of prior bDMARDs; the proportions of patients previous treated with ≥ 3 bDMARDs achieving ACR20 were significantly (p < 0.001) greater with filgotinib 200 mg (70.3%) and filgotinib 100 mg (58.8%) than with placebo (17.6%) [12]. Significant improvements with filgotinib compared with placebo were also observed in key secondary endpoints at week 12, including change from baseline in HAQ-DI, and proportions of patients achieving DAS28-CRP ≤ 3.2 (Table 2). DAS28-CRP < 2.6 and ACR50/70 response rates were also higher with filgotinib than with placebo at week 12 (p ≤ 0.05) (Table 2). Filgotinib showed sustained efficacy through week 24 (Table 2).

Limited or No Prior Exposure to Methotrexate

Filgotinib plus methotrexate therapy improved the signs and symptoms of RA, improved physical function and appeared to inhibit the progression of structural joint damage compared with methotrexate alone in patients who had moderate to severe active RA with limited or no prior methotrexate exposure in the FINCH 3 trial [13]. The ACR20 response rate was significantly higher with filgotinib 200 mg plus methotrexate than with methotrexate alone following 24 weeks of treatment (Table 2). Significant improvements were also observed in key secondary endpoints at week 24, including the ACR20 response rate with filgotinib 100 mg plus methotrexate therapy compared with methotrexate alone, and change from baseline in HAQ-DI and proportion of patients achieving DAS28-CRP < 2.6 with filgotinib 200 mg or 100 mg plus methotrexate compared with methotrexate alone (Table 2). DAS28-CRP ≤ 3.2 and ACR50/70 response rates were also higher with filgotinib 200 mg or 100 mg plus methotrexate than with methotrexate alone at week 24 (nominal p < 0.01) (Table 2).

Although the ACR20 response rate was not significantly different between filgotinib 200 mg monotherapy and methotrexate monotherapy at week 24, the change from baseline in HAQ-DI and response rates for DAS28-CRP ≤ 3.2, DAS28-CRP < 2.6 and ACR50/70 were higher with filgotinib 200 mg monotherapy than with methotrexate monotherapy at week 24 (nominal p < 0.05) (Table 2). Filgotinib 200 mg monotherapy, but not filgotinib 200 mg or 100 mg plus methotrexate, was associated with less radiographic progression compared with methotrexate alone (least-squares mean change from baseline to week 24 in mTSS − 0.1 with filgotinib 200 mg monotherapy vs 0.4 with methotrexate alone; nominal p = 0.006) [13].

Filgotinib showed sustained efficacy (e.g. higher DAS28-CRP ≤ 3.2, DAS28-CRP < 2.6 and ACR20/50/70 response rates with filgotinib plus methotrexate or filgotinib monotherapy than with methotrexate alone) through week 52 (Table 2). At week 52, patients receiving filgotinib 200 mg plus methotrexate, filgotinib 100 mg plus methotrexate or filgotinib 200 mg monotherapy had less radiographic disease than patients receiving methotrexate alone (0.21, 0.27, 0.23 vs 0.74; exploratory p < 0.05) [13].

What is the Tolerability Profile of Filgotinib?

Filgotinib was generally well tolerated in patients with RA in clinical trials. In pooled week 12 data from patients with RA who received filgotinib 200 mg (n = 777), filgotinib 100 mg (n = 788) or placebo (n = 781) in the placebo-controlled DARWIN 1 and 2 and FINCH 1 and 2 trials, common adverse reactions included nausea (3.5%) [generally transient], upper respiratory tract infection (URTI; 3.3%), urinary tract infection (UTI; 1.7%) and dizziness (1.2%). Neutropenia was uncommon [5, 6, 16]. Over 12 weeks, the incidence of infections was 17.9% with filgotinib 200 mg, 15.6% with filgotinib 100 mg and 13.3% with placebo [16], none of which were opportunistic infections (this categorisation excluded tuberculosis) [5]. Infectious adverse drug reactions reported during 12 weeks’ treatment were URTI (3.3% with filgotinib and 1.8% with placebo), UTI (1.7% and 0.9%), pneumonia (0.6% and 0.4%) and herpes zoster (0.1% and 0.3%). The incidence of serious infections was 1.0% with filgotinib 200 mg, 0.9% with filgotinib 100 mg and 0.6% with placebo [5, 16].

Interim results from two ongoing safety studies evaluating the effect of filgotinib on sperm parameters (MANTA-RAy in men with active RA, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis; MANTA in men with inflammatory bowel disease) indicate that at week 13, 6.7% (8/120 patients) of filgotinib 200 mg once daily recipients and 8.3% (10/120) of placebo recipients had a ≥ 50% decline in sperm concentration [17].

The safety profile of filgotinib longer term was similar to that in the phase 2 and 3 trials [5, 18]. No new safety concerns were identified in an integrated analysis of seven RA trials [DARWIN 1–3 and FINCH 1–4 (DARWIN 3 [18] and FINCH 4 [19] are long-term extension studies)] [20]. In a data cut including DARWIN 3 data through April 2019 and FINCH 4 data through September 2019, patients had received at least one dose of filgotinib 200 mg (n = 2267) or filgotinib 100 mg (n = 1640) for 4047.7 and 2032.9 patient-years exposure (PYE; calculated as the total exposure time in years), respectively [6]. In filgotinib 200 mg, filgotinib 100 mg, adalimumab, methotrexate and placebo recipients, the overall exposure-adjusted incidence rates (EAIRs)/100 PYEs for serious treatment-emergent adverse events (TEAEs) were 6.3, 8.2, 7.6, 7.9 and 10.3 [pneumonia was the most common across the active treatment groups (0.4, 0.5, 0.7, 0.8)] and TE death were 0.3, 0.3, 0.3, 0 and 0.3 [6].

In terms of AEs of special interest (AESIs) in the integrated analysis [6], the overall EAIRs/100 PYEs in filgotinib 200 mg, filgotinib 100 mg, adalimumab, methotrexate and placebo recipients for infections were 26.5, 31.9, 44.5, 44.1 and 55.2, serious infections were 1.7, 2.5, 3.4, 2.2 and 2.3, herpes zoster virus infections were 1.8, 1.1, 0.7, 1.1 and 1.0, opportunistic infections were 0.1, 0.2, 0.7, 0.6 and 0, venous thromboembolism were 0.2, 0, 0.3, 0.6 and 0.7, nonmelanoma skin cancer were 0.2, 0.1, 0, 0.3 and 0, malignancy excluding nonmelanoma skin cancer were 0.5, 0.5, 0.7, 1.1 and 1.0 and major adverse cardiovascular events (MACE) were 0.5, 0.6, 0.3, 0.6 and 1.0. Dose-dependency was not observed for the most important AESIs of MACE, malignancy or serious infections [6]. Among as-treated patients, the incidence of herpes zoster PYEs in filgotinib 200 mg, filgotinib 100 mg, adalimumab, methotrexate and placebo recipients was 3.3%, 1.4%, 0.6%, 1.0% and 0.4%. Most herpes zoster events were mild to moderate in severity. Multivariate analysis showed that a prior history of herpes zoster, Asian region, and age ≥ 50 years were associated with increased risk of herpes zoster infection during filgotinib treatment [21]. Although data are limited, a higher incidence of serious infections occurred in patients aged ≥ 75 years (compared to those aged < 75 years) in the filgotinib and adalimumab treatment groups; a lower starting dose of filgotinib is therefore recommended in patients aged ≥ 75 years [5, 6].

What is the Current Clinical Position of Filgotinib in RA?

Filgotinib is the fourth JAK inhibitor [6] (and one of two second-generation JAK inhibitors [4]) to be approved for the treatment of RA in the EU [6]. Filgotinib, as monotherapy or in combination with methotrexate, is an effective and generally well tolerated treatment option for adults with moderate to severe active RA with an inadequate response or intolerance to ≥ 1 DMARD, with the convenience of once-daily oral administration.

According to the 2019 European League Against Rheumatism (EULAR) recommendations for the management of RA, JAK inhibitors are recommended as an alternative to bDMARDs [2]. Methotrexate (the anchor drug in RA) is recommended as part of the initial treatment strategy (e.g. methotrexate plus short-term glucocorticoids). If there is a contraindication or early intolerance to methotrexate therapy, the (first) treatment strategy should include leflunomide or sulfasalazine. If the response is insufficient (no improvement within 3 months, or treatment target not reached by 6 months), treatment should be adjusted based on the presence or absence of poor prognostic factors. These are defined as persistently moderate or high disease activity (according to composite measures including joint counts) despite csDMARD therapy, failure of ≥ 2 csDMARDs, high swollen joint count, presence of early erosions, high acute phase reactant levels, and presence of the autoantibodies RF and/or ACPA (especially at high levels) [2].

In the absence of poor prognostic factors, a different csDMARD should be attempted, or a second csDMARD should be added on [2]. If poor prognostic factors are present, a bDMARD or a tsDMARD should be added to the treatment regimen [2]. Currently, the term tsDMARDs refers solely to JAK inhibitors, including tofacitinib, baricitinib, upadacitinib and filgotinib [22]. Since bDMARDs and JAK inhibitors are considered to have similar efficacy, the EULAR recommendations state that no preference can be given to either group for reasons of efficacy [2]. Instead, treatment choice may be driven by patient preference (e.g. oral route of administration) [22]. Second-generation JAK inhibitors such as upadacitinib and filgotinib may have a better safety profile than first-generation JAK inhibitors due to preferential inhibitory activity [1].

Recent NICE guidance [23] recommends filgotinib as an option in combination with methotrexate in adults with moderate or severe active RA (DAS28 ≥ 3.2) that has responded inadequately to ≥ 2 csDMARDs; adults with severe RA (DAS28 > 5) whose disease has responded inadequately to or who cannot have other DMARDS, including ≥ 1 bDMARD and they cannot have rituximab; and in adults with severe RA that has responded inadequately to rituximab and ≥ 1 bDMARD.

Filgotinib is also recommended as monotherapy in adults with moderate to severe or severe RA when methotrexate is contraindicated or cannot be tolerated [23].

Filgotinib as monotherapy or in combination with csDMARDs is effective in treating moderate to severe active RA in patients with an inadequate response or intolerance to DMARDs, providing clinically relevant disease remission or low disease activity rates, improvements in the signs and symptoms of RA and slowing of radiographic progression. Filgotinib is also as effective as adalimumab in achieving low disease activity in patients with an inadequate response to methotrextate.

Filgotinib is generally well tolerated, with the most frequently reported adverse reactions being nausea, URTI, UTI and dizziness. The frequency of serious infection with filgotinib is low and stable with longer-term exposure; the most common serious infection is pneumonia. Herpes zoster infections in the filgotinib 200 and 100 mg, active control (adalimumab, methotrexate) and placebo treatment groups in clinical trials were of comparable and low frequency. Most herpes zoster events were mild to moderate in severity; risk factors for herpes zoster infection with filgotinib include age (≥ 50 years), previous herpes zoster infection and geographic location (Asia). Long-term safety evaluation in the DARWIN 3 and FINCH 4 trials is ongoing; no new safety concerns have been identified to date.

Randomized, controlled studies comparing filgotinib with other JAK inhibitors have not been conducted. Indirect comparisons using systematic reviews and meta-analyses suggest that all four approved JAK inhibitors (tofacitinib, baricitinib, upadacitinib and filgotinib) are effective options in the management of RA with inadequate responses to csDMARDs or bDMARDs, although there are some differences in their efficacy and tolerability profiles [24-27]. The risk of infection appears to be similar among approved JAK inhibitors, although herpes zoster infections may be less frequent with filgotinib [28-30]. Longer-term and real-world efficacy and safety data and cost-effectiveness analyses will be useful in further positioning filgotinib relative to other treatment options (including JAK inhibitors) in these patients.

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 52 kb)

Digital Features for this Adis Drug Q&A can be found at https://doi.org/10.6084/m9.figshare.14562627.

Second-generation JAK inhibitor with preferential inhibition of JAK1 over JAK2, JAK3 and TYK2.

As monotherapy or combination therapy, improves RA signs and symptoms as well as physical function and inhibits the progression of structural joint damage.

Noninferior to adalimumab in terms of achieving low disease activity.

Generally well tolerated.